Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPACE-T: Tarlatamab in SCLC with ECOG PS 2
NCT07803848Phase 2Recruiting
- Sponsor
- AIO-Studien
- Start
- Jan 2025
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
A Phase 2 trial of tarlatamab in small cell lung cancer (SCLC), sponsored by AIO-Studien. Started Jan 2025; status: recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07803848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07803848.